Submitted by Anonymous (not verified) on 2 December 2025 - 14:16
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 15, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 15, Status: Authorised